AGIO up +1.82% percent Today $AGIO High is at 85.4

AGIO up +1.82% percent Today $AGIO High is at 85.45 and the Low 81.48 with current volume of 288,621.

Recent News posted below.

Agios Pharmaceuticals Inc AGIO other info.
http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.14 (+0.01), PCMI: 8.60 (-0.20), ACHN: 13.10 (+0.25), TGTX: 12.80 (+0.25), AGIO: 83.94 (+2.16), LIOX: 5.33 (-0.21), PLNR: 6.78 (-0.90)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 173.84 (+1.69), SLXP: 96.86 (+2.99), ICPT: 174.19 (-2.16), IBB: 297.01 (+1.81), AGIO: 83.94 (+2.16)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 83.94 (+2.16)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.39 (+0.01), ANET: 76.64 (-0.15), TKMR: 16.17 (-0.31), ORBC: 6.37 (+0.30), MDRX: 11.09 (-0.19), RMTI: 11.15 (+0.25), CTIC: 2.19 (+0.05), SHLD: 37.86 (-0.86), UBNT: 28.56 (-0.64), RIG: 28.91 (-0.37), KGC: 2.42 (+0.08), APT: 3.02 (-0.09), ANF: 28.98 (+0.29), MITK: 3.37 (+0.22), ZNGA: 2.65 (+0.17), CNET: 2.14 (-0.01), KING: 13.80 (+0.06), NETE: 1.53 (+0.04), SLXP: 96.86 (+2.99), RPRX: 9.10 (-0.12), NADL: 5.00 (-0.12), PGNX: 6.51 (+0.54), AVNR: 13.35 (+0.13), FSLR: 51.39 (-0.57), DVA: 74.97 (+0.25), NDLS: 24.10 (-0.47), ICPT: 174.19 (-2.16), AGIO: 83.94 (+2.16), PLNR: 6.78 (-0.90)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 83.94 (+2.16)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 83.94 (+2.16)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 83.94 (+2.16)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.47 (-0.84), ERF: 15.17 (+0.76), LXP: 10.98 (-0.05), PGEM: 13.08 (+0.06), CCOI: 34.28 (+1.01), TTI: 8.62 (+0.04), SJI: 58.22 (+0.24), NXST: 44.92 (+0.40), VSAT: 62.93 (-0.08), MT: 12.12 (-0.13), LXU: 30.90 (-0.59), HUM: 134.50 (+2.04), PGNX: 6.51 (+0.54), MHR: 4.54 (+0.01), CTB: 32.66 (-0.07), IDRA: 2.60 (+0.07), ISIS: 51.06 (+3.83), BPL: 77.15 (-1.47), SSP: 18.41 (-0.15), AGIO: 83.94 (+2.16), EBIX: 16.52 (+0.92)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 93.62 (+0.39), RNA: 12.03 (+0.03), AGIO: 83.94 (+2.16), CELG: 107.99 (-0.02)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 83.94 (+2.16)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.17 (-0.43), LNKD: 227.70 (-1.55), HAL: 53.01 (-0.62), AGIO: 83.94 (+2.16), IMPV: 43.26 (+0.17)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.55 (+1.53), CLVS: 61.25 (+1.11), ARWR: 6.33 (+0.12), ACHN: 13.09 (+0.24), MRK: 59.57 (+0.76), RTRX: 10.90 (+0.16), RGLS: 20.49 (-0.42), EPZM: 24.75 (+0.88), AGIO: 83.94 (+2.16), RMTI: 11.15 (+0.25), ARNA: 4.50 (+0.10), KERX: 16.17 (-0.26)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 192.15 (+0.35), RICE: 28.48 (+0.52), ISIS: 51.09 (+3.86), CYBR: 34.33 (-0.55), GNC: 43.20 (+0.15), HAL: 53.01 (-0.62), AGIO: 83.94 (+2.16), FTNT: 27.14 (+0.02)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 47.11 (-0.27), RICE: 28.48 (+0.52), GS: 192.15 (+0.35), FEYE: 32.36 (-0.03), ISIS: 51.09 (+3.86), CYBR: 34.33 (-0.55), GNC: 43.20 (+0.15), HAL: 53.01 (-0.62), EOG: 98.10 (-0.40), AGIO: 83.94 (+2.16), FTNT: 27.14 (+0.02)

Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 56.26 (-0.31), FEYE: 32.36 (-0.03), CYBR: 34.33 (-0.55), FB: 74.30 (-0.70), GNC: 43.20 (+0.15), HAL: 53.01 (-0.62), AGCO: 45.13 (-0.11), BWLD: 161.50 (+2.27), MAS: 23.22 (+0.04), YHOO: 48.70 (-0.71), WHR: 175.50 (+1.71), VSI: 47.11 (-0.27), SAVE: 79.18 (+0.13), RICE: 28.48 (+0.52), GS: 192.15 (+0.35), PH: 127.68 (-0.75), ISIS: 51.09 (+3.86), CMI: 146.01 (-0.49), EOG: 98.10 (-0.40), AGIO: 83.94 (+2.16), TWTR: 39.14 (-0.45), FTNT: 27.14 (+0.02), BABA: 115.68 (-3.47)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 21.90 (+1.61), AGIO: 83.94 (+2.16), CELG: 107.99 (-0.02)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for  MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 52.83 (-0.67), NVAX: 5.36 (+0.15), AGIO: 83.94 (+2.16), SNY: 46.66 (+0.47), MNKD: 6.07 (+0.19), CELG: 107.99 (-0.02)

Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 83.94 (+2.16)

Fab Four - Got To Get You Into My Life
Leonard Yaffe - at Seeking Alpha - Fri Oct 24, 12:24PM CDT

GILD: 108.55 (+1.53), MRK: 59.57 (+0.76), AGIO: 83.94 (+2.16), REGN: 397.30 (+11.33)